Market News AIOpen the app

OMER stock news · Omeros Corporation

Stories about Omeros Corporation (OMER) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for OMER

Follow Omeros Corporation (OMER) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OMER
Free on the App Store and Google Play, or on the web.
  1. Oct 16, 2026, 7:03 AM ET · Market

    Omeros shares dropped after Europe said no to narsoplimab, and its special use program is ending.

    Neutral

    Omeros received another negative EU opinion for narsoplimab and plans to end compassionate use. Its approved U.S. drug is gaining sales, leaving the company's overall picture mixed.

  2. Sep 22, 2026, 8:27 AM ET · Opinion

    A Plexus analyst is feeling positive and shares the top 5 company upgrades for Tuesday.

    Good for OMER

    Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 target, increasing analyst support and attention; Omeros closed at $18.49 on Monday.

  3. Aug 13, 2026, 5:22 AM ET · Market

    Omeros stock jumps more than 17% in pre-market as 20 other shares show notable movement.

    Good for OMER

    Omeros shares surged over 17% in pre-market trading following the release of its second-quarter financial results, which showed earnings of 2 cents per share against an expected loss of 27 cents, and sales of $28.529 million, far exceeding the $12.700 million consensus estimate. This strong performance indicates a positive shift in the company's financial health and investor sentiment.